E066 Baseline characteristics of patients initiating ixekizumab, secukinumab or a tumour necrosis factor inhibitor by country in the 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment - PRO-SPIRIT

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2024-04, Vol.63 (Supplement_1)
Main Authors: Gullick, Nicola, Sheesh, Mohamed, Laedermann, Cedric, Ngantcha, Marcus, Gittens, Beatrice, Ng, Khai Jing, Tillett, William, Morel, Jacques, Lubrano, Ennio, Alten, Rieke, Kristensen, Lars Erik, Chandran, Vinod, Martinez-Ferrer, Angels, Kirkham, Bruce
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue Supplement_1
container_start_page
container_title Rheumatology (Oxford, England)
container_volume 63
creator Gullick, Nicola
Sheesh, Mohamed
Laedermann, Cedric
Ngantcha, Marcus
Gittens, Beatrice
Ng, Khai Jing
Tillett, William
Morel, Jacques
Lubrano, Ennio
Alten, Rieke
Kristensen, Lars Erik
Chandran, Vinod
Martinez-Ferrer, Angels
Kirkham, Bruce
description
doi_str_mv 10.1093/rheumatology/keae163.293
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_rheumatology_keae163_293</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_rheumatology_keae163_293</sourcerecordid><originalsourceid>FETCH-LOGICAL-c993-9803405ac5f80b519a0de08af7a6a23269d62f35563085c98c7894220af55da03</originalsourceid><addsrcrecordid>eNpNUcFq3DAQNSWFJtv-w3xAnciS5VjHNKTtQmBNsncz1o5jddfSIsmhzqnQP-05HxGZhNDTzJth3nvDyzIo2HnBlLjwA00jRndwD_PFnpCKSpxzJT5kp0VZ8ZwJwU_ee15-ys5C-MUYk4WoT7PnG1ZV__78_YaBDsYS6AE96kjehGh0ANfDEaMhGwMYa6JJwD6A-U1785SUu68QSE97YxcAzgNCnEY3ebCkvQsmQJ8I08LYwXRm6boZtJts9HMaQhwIeJmPzsYBmnRyJB3NI0ETnF_0NFz5OPgkHmDTBfKPaegsHuA-Trt58diQT0qRrKYFbj1hHJNpyKG52-T3zfpuvf2cfezxEOjLW11l2-832-uf-e3mx_r66jbXSolc1UyUTKKWfc06WShkO2I19pdYIRe8UruK90LKSrBaalXry1qVnDPspdwhE6usfqVd3g-e-vbozYh-bgvWLqG1_4fWvoXWptDEC2Gjl04</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>E066 Baseline characteristics of patients initiating ixekizumab, secukinumab or a tumour necrosis factor inhibitor by country in the 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment - PRO-SPIRIT</title><source>Oxford Journals Online</source><creator>Gullick, Nicola ; Sheesh, Mohamed ; Laedermann, Cedric ; Ngantcha, Marcus ; Gittens, Beatrice ; Ng, Khai Jing ; Tillett, William ; Morel, Jacques ; Lubrano, Ennio ; Alten, Rieke ; Kristensen, Lars Erik ; Chandran, Vinod ; Martinez-Ferrer, Angels ; Kirkham, Bruce</creator><creatorcontrib>Gullick, Nicola ; Sheesh, Mohamed ; Laedermann, Cedric ; Ngantcha, Marcus ; Gittens, Beatrice ; Ng, Khai Jing ; Tillett, William ; Morel, Jacques ; Lubrano, Ennio ; Alten, Rieke ; Kristensen, Lars Erik ; Chandran, Vinod ; Martinez-Ferrer, Angels ; Kirkham, Bruce</creatorcontrib><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keae163.293</identifier><language>eng</language><ispartof>Rheumatology (Oxford, England), 2024-04, Vol.63 (Supplement_1)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Gullick, Nicola</creatorcontrib><creatorcontrib>Sheesh, Mohamed</creatorcontrib><creatorcontrib>Laedermann, Cedric</creatorcontrib><creatorcontrib>Ngantcha, Marcus</creatorcontrib><creatorcontrib>Gittens, Beatrice</creatorcontrib><creatorcontrib>Ng, Khai Jing</creatorcontrib><creatorcontrib>Tillett, William</creatorcontrib><creatorcontrib>Morel, Jacques</creatorcontrib><creatorcontrib>Lubrano, Ennio</creatorcontrib><creatorcontrib>Alten, Rieke</creatorcontrib><creatorcontrib>Kristensen, Lars Erik</creatorcontrib><creatorcontrib>Chandran, Vinod</creatorcontrib><creatorcontrib>Martinez-Ferrer, Angels</creatorcontrib><creatorcontrib>Kirkham, Bruce</creatorcontrib><title>E066 Baseline characteristics of patients initiating ixekizumab, secukinumab or a tumour necrosis factor inhibitor by country in the 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment - PRO-SPIRIT</title><title>Rheumatology (Oxford, England)</title><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNUcFq3DAQNSWFJtv-w3xAnciS5VjHNKTtQmBNsncz1o5jddfSIsmhzqnQP-05HxGZhNDTzJth3nvDyzIo2HnBlLjwA00jRndwD_PFnpCKSpxzJT5kp0VZ8ZwJwU_ee15-ys5C-MUYk4WoT7PnG1ZV__78_YaBDsYS6AE96kjehGh0ANfDEaMhGwMYa6JJwD6A-U1785SUu68QSE97YxcAzgNCnEY3ebCkvQsmQJ8I08LYwXRm6boZtJts9HMaQhwIeJmPzsYBmnRyJB3NI0ETnF_0NFz5OPgkHmDTBfKPaegsHuA-Trt58diQT0qRrKYFbj1hHJNpyKG52-T3zfpuvf2cfezxEOjLW11l2-832-uf-e3mx_r66jbXSolc1UyUTKKWfc06WShkO2I19pdYIRe8UruK90LKSrBaalXry1qVnDPspdwhE6usfqVd3g-e-vbozYh-bgvWLqG1_4fWvoXWptDEC2Gjl04</recordid><startdate>20240424</startdate><enddate>20240424</enddate><creator>Gullick, Nicola</creator><creator>Sheesh, Mohamed</creator><creator>Laedermann, Cedric</creator><creator>Ngantcha, Marcus</creator><creator>Gittens, Beatrice</creator><creator>Ng, Khai Jing</creator><creator>Tillett, William</creator><creator>Morel, Jacques</creator><creator>Lubrano, Ennio</creator><creator>Alten, Rieke</creator><creator>Kristensen, Lars Erik</creator><creator>Chandran, Vinod</creator><creator>Martinez-Ferrer, Angels</creator><creator>Kirkham, Bruce</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20240424</creationdate><title>E066 Baseline characteristics of patients initiating ixekizumab, secukinumab or a tumour necrosis factor inhibitor by country in the 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment - PRO-SPIRIT</title><author>Gullick, Nicola ; Sheesh, Mohamed ; Laedermann, Cedric ; Ngantcha, Marcus ; Gittens, Beatrice ; Ng, Khai Jing ; Tillett, William ; Morel, Jacques ; Lubrano, Ennio ; Alten, Rieke ; Kristensen, Lars Erik ; Chandran, Vinod ; Martinez-Ferrer, Angels ; Kirkham, Bruce</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c993-9803405ac5f80b519a0de08af7a6a23269d62f35563085c98c7894220af55da03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gullick, Nicola</creatorcontrib><creatorcontrib>Sheesh, Mohamed</creatorcontrib><creatorcontrib>Laedermann, Cedric</creatorcontrib><creatorcontrib>Ngantcha, Marcus</creatorcontrib><creatorcontrib>Gittens, Beatrice</creatorcontrib><creatorcontrib>Ng, Khai Jing</creatorcontrib><creatorcontrib>Tillett, William</creatorcontrib><creatorcontrib>Morel, Jacques</creatorcontrib><creatorcontrib>Lubrano, Ennio</creatorcontrib><creatorcontrib>Alten, Rieke</creatorcontrib><creatorcontrib>Kristensen, Lars Erik</creatorcontrib><creatorcontrib>Chandran, Vinod</creatorcontrib><creatorcontrib>Martinez-Ferrer, Angels</creatorcontrib><creatorcontrib>Kirkham, Bruce</creatorcontrib><collection>CrossRef</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gullick, Nicola</au><au>Sheesh, Mohamed</au><au>Laedermann, Cedric</au><au>Ngantcha, Marcus</au><au>Gittens, Beatrice</au><au>Ng, Khai Jing</au><au>Tillett, William</au><au>Morel, Jacques</au><au>Lubrano, Ennio</au><au>Alten, Rieke</au><au>Kristensen, Lars Erik</au><au>Chandran, Vinod</au><au>Martinez-Ferrer, Angels</au><au>Kirkham, Bruce</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>E066 Baseline characteristics of patients initiating ixekizumab, secukinumab or a tumour necrosis factor inhibitor by country in the 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment - PRO-SPIRIT</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><date>2024-04-24</date><risdate>2024</risdate><volume>63</volume><issue>Supplement_1</issue><issn>1462-0324</issn><eissn>1462-0332</eissn><doi>10.1093/rheumatology/keae163.293</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1462-0324
ispartof Rheumatology (Oxford, England), 2024-04, Vol.63 (Supplement_1)
issn 1462-0324
1462-0332
language eng
recordid cdi_crossref_primary_10_1093_rheumatology_keae163_293
source Oxford Journals Online
title E066 Baseline characteristics of patients initiating ixekizumab, secukinumab or a tumour necrosis factor inhibitor by country in the 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment - PRO-SPIRIT
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T20%3A34%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=E066%E2%80%83Baseline%20characteristics%20of%20patients%20initiating%20ixekizumab,%20secukinumab%20or%20a%20tumour%20necrosis%20factor%20inhibitor%20by%20country%20in%20the%2024-month%20Prospective%20Psoriatic%20Arthritis%20Observational%20Study%20of%20Persistence%20of%20Treatment%20-%20PRO-SPIRIT&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Gullick,%20Nicola&rft.date=2024-04-24&rft.volume=63&rft.issue=Supplement_1&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keae163.293&rft_dat=%3Ccrossref%3E10_1093_rheumatology_keae163_293%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c993-9803405ac5f80b519a0de08af7a6a23269d62f35563085c98c7894220af55da03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true